Aljawharah Alrubayyi, D.Phil.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV-1 | 10 | 2024 | 6863 | 1.200 |
Why?
|
Killer Cells, Natural | 7 | 2024 | 2200 | 0.910 |
Why?
|
HIV Infections | 13 | 2024 | 17351 | 0.870 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 2 | 2024 | 303 | 0.780 |
Why?
|
Immunity, Humoral | 1 | 2021 | 606 | 0.570 |
Why?
|
Vaccines | 1 | 2023 | 844 | 0.480 |
Why?
|
Phagocytosis | 2 | 2021 | 1528 | 0.440 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2022 | 2199 | 0.440 |
Why?
|
CD4-Positive T-Lymphocytes | 5 | 2021 | 4369 | 0.370 |
Why?
|
Monocytes | 1 | 2018 | 2570 | 0.320 |
Why?
|
Flow Cytometry | 1 | 2018 | 5869 | 0.300 |
Why?
|
Antibodies, Viral | 4 | 2023 | 3156 | 0.300 |
Why?
|
T-Lymphocytes | 2 | 2021 | 10194 | 0.280 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2022 | 4580 | 0.220 |
Why?
|
Antigens, Viral | 2 | 2021 | 988 | 0.180 |
Why?
|
Mitochondrial Diseases | 1 | 2024 | 343 | 0.170 |
Why?
|
Antibody Formation | 2 | 2021 | 1395 | 0.170 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2021 | 280 | 0.160 |
Why?
|
Ebolavirus | 1 | 2021 | 251 | 0.160 |
Why?
|
Natural Killer T-Cells | 1 | 2021 | 322 | 0.150 |
Why?
|
Receptors, CCR5 | 1 | 2020 | 486 | 0.150 |
Why?
|
Antibodies | 2 | 2023 | 2418 | 0.150 |
Why?
|
Organic Chemicals | 1 | 2018 | 210 | 0.150 |
Why?
|
Immunologic Memory | 1 | 2024 | 1359 | 0.140 |
Why?
|
Cytomegalovirus Infections | 1 | 2024 | 831 | 0.140 |
Why?
|
Species Specificity | 1 | 2021 | 2414 | 0.140 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2021 | 420 | 0.130 |
Why?
|
Interferon-gamma | 2 | 2021 | 3162 | 0.130 |
Why?
|
Vaccination | 2 | 2023 | 3384 | 0.120 |
Why?
|
AIDS Vaccines | 1 | 2020 | 896 | 0.120 |
Why?
|
HIV Antibodies | 1 | 2020 | 1303 | 0.110 |
Why?
|
Colon | 1 | 2021 | 1792 | 0.110 |
Why?
|
Tissue Donors | 1 | 2021 | 2331 | 0.100 |
Why?
|
Hematologic Neoplasms | 1 | 2023 | 1896 | 0.090 |
Why?
|
Intestinal Mucosa | 1 | 2021 | 3032 | 0.090 |
Why?
|
Immunity, Innate | 1 | 2022 | 3065 | 0.090 |
Why?
|
Antiviral Agents | 1 | 2022 | 3060 | 0.080 |
Why?
|
Mitochondria | 1 | 2022 | 3624 | 0.080 |
Why?
|
Immunotherapy | 2 | 2024 | 4652 | 0.080 |
Why?
|
Genome, Human | 1 | 2021 | 4425 | 0.080 |
Why?
|
Humans | 17 | 2024 | 761504 | 0.080 |
Why?
|
Phenotype | 2 | 2024 | 16591 | 0.070 |
Why?
|
Gene Expression | 1 | 2017 | 7581 | 0.060 |
Why?
|
Interleukin-15 | 1 | 2024 | 185 | 0.050 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2021 | 1897 | 0.050 |
Why?
|
Cytokines | 3 | 2024 | 7396 | 0.050 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2020 | 5671 | 0.050 |
Why?
|
CD4-CD8 Ratio | 1 | 2021 | 114 | 0.050 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2020 | 84 | 0.050 |
Why?
|
Hepatitis B, Chronic | 1 | 2024 | 410 | 0.040 |
Why?
|
Male | 7 | 2024 | 360804 | 0.040 |
Why?
|
Neutralization Tests | 1 | 2021 | 728 | 0.040 |
Why?
|
Adult | 6 | 2024 | 221177 | 0.040 |
Why?
|
Cohort Studies | 1 | 2021 | 41487 | 0.040 |
Why?
|
Amides | 1 | 2021 | 449 | 0.040 |
Why?
|
Hepatitis B | 1 | 2024 | 705 | 0.040 |
Why?
|
Alanine | 1 | 2021 | 609 | 0.040 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2021 | 287 | 0.040 |
Why?
|
Friend murine leukemia virus | 1 | 2017 | 37 | 0.040 |
Why?
|
Complement System Proteins | 1 | 2021 | 736 | 0.040 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 1 | 2020 | 369 | 0.040 |
Why?
|
Female | 6 | 2024 | 392644 | 0.040 |
Why?
|
Retroviridae Infections | 1 | 2017 | 147 | 0.040 |
Why?
|
Semen | 1 | 2020 | 347 | 0.040 |
Why?
|
Middle Aged | 5 | 2024 | 220895 | 0.040 |
Why?
|
Enterotoxins | 1 | 2017 | 367 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2020 | 1870 | 0.030 |
Why?
|
Pyridones | 1 | 2021 | 809 | 0.030 |
Why?
|
Adenine | 1 | 2021 | 987 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2021 | 2571 | 0.030 |
Why?
|
Treatment Failure | 1 | 2021 | 2645 | 0.030 |
Why?
|
RNA, Viral | 1 | 2021 | 2846 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 1 | 2020 | 1802 | 0.030 |
Why?
|
Host-Pathogen Interactions | 1 | 2021 | 1459 | 0.030 |
Why?
|
Disease Outbreaks | 1 | 2021 | 1749 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2020 | 2547 | 0.020 |
Why?
|
Viral Load | 1 | 2020 | 3332 | 0.020 |
Why?
|
Proteomics | 1 | 2024 | 3849 | 0.020 |
Why?
|
Piperazines | 1 | 2021 | 2523 | 0.020 |
Why?
|
Survivors | 1 | 2021 | 2371 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2020 | 5486 | 0.020 |
Why?
|
Biopsy | 1 | 2020 | 6766 | 0.020 |
Why?
|
Aged | 1 | 2021 | 169289 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2020 | 4544 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2024 | 16981 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2020 | 4758 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2017 | 4352 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2020 | 4527 | 0.010 |
Why?
|
Disease Progression | 1 | 2021 | 13506 | 0.010 |
Why?
|
Young Adult | 2 | 2021 | 59243 | 0.010 |
Why?
|
Mice | 2 | 2024 | 81525 | 0.010 |
Why?
|
Time Factors | 1 | 2021 | 39967 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39106 | 0.010 |
Why?
|
Neoplasms | 1 | 2024 | 22170 | 0.010 |
Why?
|
Adolescent | 1 | 2021 | 88319 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2020 | 64680 | 0.010 |
Why?
|
Animals | 1 | 2017 | 168459 | 0.000 |
Why?
|